Clinical characteristics of 50 BMT patients evaluated for HC
| . | No HC . | HC . |
|---|---|---|
| Number | 30 | 20 |
| Male/Female | 16:14 | 10:10 |
| Age | 35 ± 2 (17-67) | 39 ± 2 (22-50) |
| Diagnosis | ||
| CML | 12 | 6 |
| AML | 8 | 4 |
| NHL | 4 | 3 |
| Others | 6 | 7 |
| BMT type | ||
| Autologous | 9 | 4 |
| Allogeneic | ||
| Related donors* | 14 | 13 |
| MUD | 7 | 3 |
| Conditioning regimens | ||
| Bu-Cy | 16 | 12 |
| Cy-TBI | 4 | 2 |
| Bu-Cy-TBI | 1 | 0 |
| CBV | 5 | 1 |
| CarboPEC | 1 | 2 |
| Melphalan | 2 | 0 |
| BEAM | 1 | 2 |
| Fludarabine-TBI | 0 | 1 |
| Acute GVHD | ||
| Nil | 21 | 8 |
| Grade 1 | 4 | 8 |
| Grade 2 or above | 5 | 4 |
| HC | ||
| Grade 1 | — | 14 |
| Grade 2 | — | 2 |
| Grade 3 | — | 1 |
| Grade 4 | — | 3 |
| . | No HC . | HC . |
|---|---|---|
| Number | 30 | 20 |
| Male/Female | 16:14 | 10:10 |
| Age | 35 ± 2 (17-67) | 39 ± 2 (22-50) |
| Diagnosis | ||
| CML | 12 | 6 |
| AML | 8 | 4 |
| NHL | 4 | 3 |
| Others | 6 | 7 |
| BMT type | ||
| Autologous | 9 | 4 |
| Allogeneic | ||
| Related donors* | 14 | 13 |
| MUD | 7 | 3 |
| Conditioning regimens | ||
| Bu-Cy | 16 | 12 |
| Cy-TBI | 4 | 2 |
| Bu-Cy-TBI | 1 | 0 |
| CBV | 5 | 1 |
| CarboPEC | 1 | 2 |
| Melphalan | 2 | 0 |
| BEAM | 1 | 2 |
| Fludarabine-TBI | 0 | 1 |
| Acute GVHD | ||
| Nil | 21 | 8 |
| Grade 1 | 4 | 8 |
| Grade 2 or above | 5 | 4 |
| HC | ||
| Grade 1 | — | 14 |
| Grade 2 | — | 2 |
| Grade 3 | — | 1 |
| Grade 4 | — | 3 |
CML indicates chronic myelogenous leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; Bu-Cy, busulfan/cyclophosphamide; CBV, cyclophosphamide, BCNU, etoposide; CarboPEC, carboplatin, etoposide, cyclophosphamide; BEAM, BCNU, etoposide, cytarabine arabinoside, melphalan.
HLA-identical sibling (n = 24), one HLA-mismatched parent (n = 2), syngeneic donor (n = 1).